Research Analysts Offer Predictions for SLDB FY2025 Earnings

Key Points

• Analyst Cantor Fitzgerald has raised its FY2025 EPS estimate for Solid Biosciences to ($1.86) per share from a previous estimate of ($2.06), maintaining an "Overweight" rating and a $16 target price.
• The company reported a quarterly EPS of ($0.42), exceeding analysts' consensus expectation of ($0.51) by $0.09.
• Solid Biosciences' current stock has a consensus rating of "Buy," with several analysts setting target prices between $14 and $20.

Solid Biosciences Inc. (NASDAQ:SLDB - Free Report) - Analysts at Cantor Fitzgerald upped their FY2025 EPS estimates for Solid Biosciences in a report issued on Wednesday, August 13th. Cantor Fitzgerald analyst K. Kluska now forecasts that the company will post earnings per share of ($1.86) for the year, up from their prior estimate of ($2.06). Cantor Fitzgerald currently has a "Overweight" rating and a $16.00 target price on the stock. The consensus estimate for Solid Biosciences' current full-year earnings is ($2.84) per share. Cantor Fitzgerald also issued estimates for Solid Biosciences' FY2026 earnings at ($1.93) EPS.

Solid Biosciences (NASDAQ:SLDB - Get Free Report) last released its quarterly earnings data on Tuesday, August 12th. The company reported ($0.42) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.51) by $0.09.

Several other equities research analysts also recently weighed in on the stock. Wall Street Zen upgraded shares of Solid Biosciences from a "sell" rating to a "hold" rating in a research note on Saturday. Citigroup initiated coverage on shares of Solid Biosciences in a research note on Thursday, June 26th. They issued a "buy" rating and a $14.00 target price for the company. JMP Securities restated a "market outperform" rating and issued a $15.00 target price on shares of Solid Biosciences in a research note on Friday, June 6th. HC Wainwright restated a "buy" rating and issued a $20.00 target price on shares of Solid Biosciences in a research note on Tuesday, June 17th. Finally, Chardan Capital reaffirmed a "buy" rating and issued a $15.00 price target on shares of Solid Biosciences in a report on Thursday, August 14th. Two analysts have rated the stock with a Strong Buy rating and ten have given a Buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of "Buy" and a consensus target price of $15.00.

Solid Biosciences Stock Performance

SLDB traded down $0.14 during trading on Friday, hitting $5.66. The stock had a trading volume of 922,476 shares, compared to its average volume of 1,921,308. The company has a market capitalization of $440.74 million, a PE ratio of -2.02 and a beta of 2.44. Solid Biosciences has a twelve month low of $2.41 and a twelve month high of $10.37. The stock has a 50 day simple moving average of $5.67 and a two-hundred day simple moving average of $4.48.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. JPMorgan Chase & Co. raised its holdings in shares of Solid Biosciences by 9,393.8% during the fourth quarter. JPMorgan Chase & Co. now owns 955,932 shares of the company's stock worth $3,824,000 after purchasing an additional 945,863 shares during the last quarter. Renaissance Technologies LLC raised its holdings in shares of Solid Biosciences by 12.7% during the fourth quarter. Renaissance Technologies LLC now owns 82,493 shares of the company's stock worth $330,000 after purchasing an additional 9,281 shares during the last quarter. Bank of America Corp DE raised its holdings in shares of Solid Biosciences by 87.9% during the fourth quarter. Bank of America Corp DE now owns 83,471 shares of the company's stock worth $334,000 after purchasing an additional 39,056 shares during the last quarter. Allianz Asset Management GmbH acquired a new stake in Solid Biosciences during the first quarter valued at $100,000. Finally, Knott David M Jr acquired a new stake in Solid Biosciences during the first quarter valued at $488,000. Hedge funds and other institutional investors own 81.46% of the company's stock.

Solid Biosciences Company Profile

Solid Biosciences Inc, a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia.